SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
(Nasdaq: RDEA) today announced that preclinical data will be presented on
the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,
at the 20th European Organisation for Research and Treatment of Cancer
(EORTC) -- National Cancer Institute (NCI) -- American Association for
Cancer Research (AACR) symposium on 'Molecular Targets and Cancer
Therapeutics' in Geneva, Switzerland.
The presentation details are as follows:
Date/Time: Friday, October 24 from 12:00 p.m. - 2:00 p.m. CEST
Abstract Title: "Selective MEK Inhibitor RDEA119 exhibits efficacy in
orthotopic hepatoma models and cytostatic potential in
multiple cell based models of cancer"
Session Title: Signal Transduction Modulators
Location: Poster Hall, GenevaPalExpo
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, gout, cancer and inflammatory
diseases. We have five product candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product candidate
is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which
has successfully completed a Phase 2a study for the treatment of patients
with HIV. We have evaluated our second-generation NNRTI for the treatment
of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have
selected it for clinical development. RDEA594, our lead product candidate
for the treatment of gout, is being evaluated in a Phase 1
|SOURCE Ardea Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved